Update on the use of abatacept for the treatment of rheumatoid arthritis

Expert Review of Clinical Immunology

Volumn 9, Issue 7, 2013, Pages 599-621

  Vicente Rabaneda, Esther F ^a   Herrero Beaumont, Gabriel ^b   Castañeda, Santos ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

abatacept; adverse events; clinical efficacy; pharmacokinetics; radiographic progression; safety

Indexed keywords

ABATACEPT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE;

ARTICLE; AUTOIMMUNE DISEASE; COMORBIDITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INFECTION; INJECTION SITE REACTION; NEOPLASM; PHARMACODYNAMICS; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SKIN CANCER; SQUAMOUS CELL CARCINOMA; VACCINATION;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARTHROGRAPHY; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DRUG RESISTANCE; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; JOINTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84883247111     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2013.811192     Document Type: Article

References (82)

1. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum. 27(8), 864-872 (1984).
2. Wolfe F. The natural history of rheumatoid arthritis. J. Rheumatol. Suppl. 44, 13-22 (1996).
3. Carmona L, Villaverde V, Hernández-García C, Ballina J, Gabriel R, Laffon A; EPISER Study Group. The prevalence of rheumatoid arthritis in the general population of Spain. Rheumatology (Oxford). 41(1), 88-95 (2002).
4. Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 22(2 Suppl. 1), 1-12 (2004).
5. Chan ES, Cronstein BN. Methotrexate-how does it really work Nat. Rev. Rheumatol. 6(3), 175-178 (2010).
6. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat. Rev. Drug Discov. 2(6), 473-488 (2003).
7. Singh R, Robinson DB, El-Gabalawy HS. Emerging biologic therapies in rheumatoid arthritis: cell targets and cytokines. Curr. Opin. Rheumatol. 17(3), 274-279 (2005).
8. Choi SI, Brahn E. Rheumatoid arthritis therapy: advances from bench to bedside. Autoimmunity 43(7), 478-492 (2010).
9. Smolen JS, Aletaha D, Bijlsma JW et al.; T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis. 69(4), 631-637 (2010).
10. Teng GG, Turkiewicz AM, Moreland LW. Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis. Expert Opin. Biol. Ther. 5(9), 1245-1254 (2005).
11. Dall'Era M, Davis J. CTLA4Ig: a novel inhibitor of costimulation. Lupus 13(5), 372-376 (2004).
12. Janeway CA, Travers P. The immune system in health and disease. In: Immunobiology, The Immune System in Health and Diseases. Janeway CA, Travers P, Walport M, Schlomchik MJ (Eds). Garland Science Publishing, New York, NY, USA, 461-613 (2005).
13. Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J. Am. Soc. Nephrol. 13(2), 559-575 (2002).
14. Dubois EA, Cohen AF. New drug mechanisms. Abatacept. Br. J. Clin. Pharmacol. 68(4), 480-481 (2009).
15. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344(12), 907-916 (2001).
16. Perkins D, Wang Z, Donovan C et al. Regulation of CTLA-4 expression during T cell activation. J. Immunol. 156(11), 4154-4159 (1996).
17. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174(3), 561-569 (1991).
18. Korhonen R, Moilanen E. Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis. Basic Clin. Pharmacol. Toxicol. 104(4), 276-284 (2009).
19. Moreland L, Bate G, Kirkpatrick P. Abatacept. Nat. Rev. Drug Discov. 5(3), 185-186 (2006).
20. Cutolo M, Nadler SG. Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis. Autoimmun. Rev. 12(7), 758-767 (2013).
21. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 265(5176), 1225-1227 (1994).
22. Webb LM, Walmsley MJ, Feldmann M. Prevention and amelioration of collageninduced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur. J. Immunol. 26(10), 2320-2328 (1996).
23. Moreland LW, Alten R, Van den Bosch F et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 46(6), 1470-1479 (2002).
24. Kremer JM, Westhovens R, Leon M et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349(20), 1907-1915 (2003).
25. Kremer JM, Dougados M, Emery P et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a Phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 52(8), 2263-2271 (2005).
26. Kremer JM, Genant HK, Moreland LW et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 144(12), 865-876 (2006).
27. Schiff M, Keiserman M, Codding C et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a Phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann. Rheum. Dis. 67(8), 1096-1103 (2008).
28. Westhovens R, Kremer JM, Moreland LW et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended Phase IIB study. J. Rheumatol. 36(4), 736-742 (2009).
29. Schiff M. Abatacept treatment for rheumatoid arthritis. Rheumatology (Oxford). 50(3), 437-449 (2011).
30. Kremer JM, Genant HK, Moreland LW et al. Results of a two-year follow-up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 58(4), 953-963 (2008).
31. Kremer JM, Russell AS, Emery P et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann. Rheum. Dis. 70(10), 1826-1830 (2011).
32. Schiff M, Keiserman M, Codding C et al. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study. Ann. Rheum. Dis. 70(11), 2003-2007 (2011).
33. Genovese MC, Becker JC, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 353(11), 1114-1123 (2005).
34. Genovese MC, Schiff M, Luggen M et al. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy. J. Rheumatol. 39(8), 1546-1554 (2012).
35. Schiff M, Pritchard C, Huffstutter JE et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann. Rheum. Dis. 68(11), 1708-1714 (2009).
36. D'Agostino MA, Wakefield R, Berner Hammer H et al. The relationship between power Doppler ultrasonography outcomes and clinical efficacy in abatacept-treated patients with rheumatoid arthritis and in inadequate response to methotrexate. Proceedings of the 76th American College of Rheumatology Annual Meeting. Washington, DC, USA (Poster 811). Arthritis Rheum. 64(Suppl. 10), S353 (2012).
37. Westhovens R, Robles M, Ximenes AC et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann. Rheum. Dis. 68(12), 1870-1877 (2009).
38. Emery P, Durez P, Dougados M et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann. Rheum. Dis. 69(3), 510-516 (2010).
39. Bathon J, Robles M, Ximenes AC et al. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Ann. Rheum. Dis. 70(11), 1949-1956 (2011).
40. Yazici Y, Moniz Reed D, Klem C, Rosenblatt L, Wu G, Kremer JM. Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data. Clin. Exp. Rheumatol. 29(3), 494-499 (2011).
41. Genant HK, Peterfy CG, Westhovens R et al. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann. Rheum. Dis. 67(8), 1084-1089 (2008).
42. Conaghan PG, Durez P, Alten RE et al. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Ann. Rheum. Dis. doi:10.1136/annrheumdis-2012-201611 (2012) (Epub ahead of print).
43. Buch MH, Boyle DL, Rosengren S et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann. Rheum. Dis. 68(7), 1220-1227 (2009).
44. Corbo M, Valencia X, Raymond R et al. A subcutaneous administration regimen for abatacept in patients with rheumatoid arthritis: pharmacokinetics, safety and immunogenicity. Proceedings of the 72nd American College of Rheumatology Annual Meeting. San Francisco, CA, USA (Poster 376). Arthritis Rheum. 58(Suppl. 9), S307 (2008).
45. Corbo M, Valencia X, Raymond R et al. Subcutaneous administration of abatacept in patients with rheumatoid arthritis: pharmacokinetics, safety and immunogenicity. Proceedings of the European League against Rheumatism Congress 2009. Copenhagen, Denmark (Poster SAT0101). Ann. Rheum. Dis. 68(Suppl. 3), 574 (2009).
46. Nash P, Nayiager S, Genovese MC et al. Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a Phase III, international, multicenter, parallel-Arm, open-label study. Arthritis Care Res. (Hoboken). 65(5), 718-728 (2013).
47. Genovese MC, Covarrubias A, Leon G et al. Subcutaneous abatacept versus intravenous abatacept: a Phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum. 63(10), 2854-2864 (2011).
48. Kaine J, Gladstein G, Strusberg I et al. Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (Phase IIIb ALLOW study). Ann. Rheum. Dis. 71(1), 38-44 (2012).
49. Keystone EC, Kremer JM, Russell A et al. Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the Phase IIIb ATTUNE study. Ann. Rheum. Dis. 71(6), 857-861 (2012).
50. Weinblatt ME, Schiff M, Valente R et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a Phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 65(1), 28-38 (2013).
51. Leffers HC, Ostergaard M, Glintborg B et al.; all departments of rheumatology in Denmark. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann. Rheum. Dis. 70(7), 1216-1222 (2011).
52. Gottenberg JE, Ravaud P, Cantagrel A et al. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry. Ann. Rheum. Dis. 71(11), 1815-1819 (2012).
53. Nüßlein H, Alten R, Galeazzi M et al. Effect of prior therapy on the efficacy and safety of abatacept: 6-month analysis of the action study. Proceedings of the European League against Rheumatism Congress 2012. Berlin, Germany (Poster AB0532). Ann. Rheum. Dis. 71(Suppl. 3), 668 (2012).
54. Nüßlein H, Alten R, Galeazzi M et al. Real-world efficacy and safety of abatacept treatment for rheumatoid arthritis: 12-month interim analysis of the action study. Proceedings of the 76th American College of Rheumatology Annual Meeting. Washington, DC, USA (Poster 460). Arthritis Rheum. 64(Suppl. 10), S199-S200 (2012).
55. Lindblad S, Stawiarz L; Swedish Rheumatology Quality Register. Gender and previous treatment influence outcomes from abatacept in a 5-year rheumatoid arthritis cohort. Ann. Rheum. Dis. 71(Suppl. 3), 383 (2012).
56. Schoels M, Aletaha D, Smolen JS, Wong JB. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor a inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-Analysis. Ann. Rheum. Dis. 71(8), 1303-1308 (2012).
57. Guyot P, Taylor PC, Christensen R et al. Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom. J. Rheumatol. 39(6), 1198-1206 (2012).
58. Kuriya B, Arkema EV, Bykerk VP, Keystone EC. Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-Analysis of clinical and radiographic remission. Ann. Rheum. Dis. 69(7), 1298-1304 (2010).
59. Du Pan SM, Scherer A, Gabay C, Finckh A. Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients. Ann. Rheum. Dis. 71(6), 997-999 (2012).
60. Pierreisnard A, Issa N, Barnetche T, Richez C, Schaeverbeke T. Meta-Analysis of clinical and radiological efficacy of biologics in rheumatoid arthritis patients naive or inadequately responsive to methotrexate. Joint. Bone. Spine doi:10.1016/j.jbspin.2012.09.023 (2012) (Epub ahead of print).
61. Genovese MC, Pacheco-Tena C, Covarrubias A et al. Subcutaneous abatacept: long-term data from the Acquire Trial. Proceedings of the 76th American College of Rheumatology Annual Meeting. Washington, DC, USA (Poster 462). Arthritis Rheum. 64(Suppl. 10), S201 (2012).
62. Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum. 54(9), 2807-2816 (2006).
63. Weinblatt M, Schiff M, Goldman A et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann. Rheum. Dis. 66(2), 228-234 (2007).
64. Genovese MC, Hochberg MC, Cohen RB et al. Prolonged exposure to subcutaneous and intravenous abatacept in patients with rheumatoid arthritis does not affect rates of infection, malignancy and autoimmune events: results from pooled clinical trial data. Proceedings of the 76th American College of Rheumatology Annual Meeting. Washington, DC, USA (Poster 1695). Arthritis Rheum. 64(Suppl. 10), S725 (2012).
65. Maxwell LJ, Singh JA. Abatacept for rheumatoid arthritis: a Cochrane systematic review. J. Rheumatol. 37(2), 234-245 (2010).
66. Singh JA, Wells GA, Christensen R et al. Adverse effects of biologics: a network meta-Analysis and Cochrane overview. Cochrane Database Syst. Rev. 2, CD008794.114 (2011).
67. Simon TA, Askling J, Lacaille D et al.; Abatacept Epidemiology Study Group. Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment. Arthritis Res. Ther. 12(2), R67 (2010).
68. Kim PS, Ho GY, Prete PE, Furst DE. Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B. Arthritis Care Res. (Hoboken) 64(8), 1265-1268 (2012).
69. Simon TA, Smitten AL, Franklin J et al. Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann. Rheum. Dis. 68(12), 1819-1826 (2009).
70. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-Analysis. JAMA 308(9), 898-908 (2012).
71. Haggerty HG, Abbott MA, Reilly TP et al. Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis. J. Rheumatol. 34(12), 2365-2373 (2007).
72. Radstake TR, Svenson M, Eijsbouts AM et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann. Rheum. Dis. 68(11), 1739-1745 (2009).
73. Dore RK, Mathews S, Schechtman J et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 25(1), 40-46 (2007).
74. Hadjinicolaou AV, Nisar MK, Bhagat S, Parfrey H, Chilvers ER, Ostör AJ. Non-infectious pulmonary complications of newer biological agents for rheumatic disease-A systematic literature review. Rheumatology (Oxford). 50(12), 2297-2305 (2011).
75. Jiménez-Alvarez L, Arreola JL, Ramírez-Martínez G et al. The effect of CTLA-4Ig, a CD28/B7 antagonist, on the lung inflammation and T cell subset profile during murine hypersensitivity pneumonitis. Exp. Mol. Pathol. 91(3), 718-722 (2011).
76. Viglietta V, Bourcier K, Buckle GJ et al. CTLA4Ig treatment in patients with multiple sclerosis: an open-label, Phase 1 clinical trial. Neurology 71(12), 917-924 (2008).
77. Smitten AL, Qi K, Simon TA, Becker J-C. Autoimmune Adverse Events in the Abatacept RA Clinical Development Program: a safety analysis with 10,000 person-years of exposure. Proceedings of the 72nd American College of Rheumatology Annual Meeting. San Francisco, CA, USA (Poster 1673). Arthritis Rheum. 58(Suppl. 9), S786 (2008).
78. Ruperto N, Lovell DJ, Quartier P et al.; Paediatric Rheumatology International Trials Organization and the Pediatric Rheumatology Collaborative Study Group. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 62(6), 1792-1802 (2010).
79. Ojeda-Uribe M, Afif N, Dahan E et al. Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. Clin. Rheumatol. 32(5), 695-700 (2013).
80. Tay L, Leon F, Vratsanos G, Raymond R, Corbo M. Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. Arthritis Res. Ther. 9(2), R38 (2007).
81. Ribeiro AC, Laurindo IM, Guedes LK et al. Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. Arthritis Care Res. (Hoboken). 65(3), 476-480 (2013).
82. Hayashi M, Kojima T, Ishiguro N, Kobayakawa T, Kanamono T. Seroresponse rates after influenza vaccination in rheumatoid arthritis patients treated with biological agents during the 2011-2012 flu season. Proceedings of the 76th American College of Rheumatology Annual Meeting. Washington, DC, USA (Poster 2465). Arthritis Rheum. 64(Suppl. 10), S1038 (2012).